Editor’s note: This is an opinion article.
In the early 2010s, when CRISPR-Cas9 first demonstrated that editing the human genome could be done with relative ease, the ethical debate was dominated by a single question: is it safe? The fear was that off-target edits, unintended mutations, and unanticipated developmental effects made human germline editing an unacceptable risk, regardless of its potential benefits.
That debate is ending, not because gene editing has been proven perfectly safe, but because the technology has matured to the point where the safety arguments are no longer an absolute barrier. Two new base-editing studies on human embryos, published in recent weeks, have demonstrated increasing precision. The Nuffield Council on Bioethics has concluded that human germline editing is “not inherently ethically unacceptable.” A 2026 Ipsos poll found that majorities in the UK, Spain, and the Netherlands now support gene editing to correct life-threatening conditions like cystic fibrosis, and a plurality support it for manageable conditions like asthma.
We are approaching a tipping point. The question is no longer whether gene-edited humans will exist. It is who will benefit from the technology.
The Slippery Slope Is Real
This is not a hypothetical concern. The Guardian’s editorial on July 5 put it plainly: the “leap from therapeutic applications to the customization of traits is shorter than many might assume.” The editorial, which reviewed the current landscape of gene-editing research and regulation, identified a pattern that should concern anyone who believes science should serve human need rather than human wealth.
In the United States, IVF companies are collaborating with laboratories conducting base-editing research. The language is always about “treating disease,” but the infrastructure being built, embryo selection, genetic profiling, the ability to modify specific genes, is the same infrastructure that could be used for enhancement. The distinction between correcting a mutation that causes cystic fibrosis and selecting for height, eye color, or cognitive traits is a line drawn in policy, not in biology.
UK couples are already seeking out companies abroad to screen for desirable traits, despite donor selection being illegal in British IVF. If people are willing to travel internationally for embryo screening, they will be willing to travel for gene editing. The market will find a way.
The Real Divide
This is where the inequality problem becomes acute. Gene editing for life-threatening conditions, the scenario that commands majority public support, would be expensive. Personalized neoantigen vaccines for glioblastoma cost tens of thousands of dollars per patient. Custom gene-editing treatments will not be cheap. If the technology is deployed primarily through private clinics serving patients who can afford to pay, it will deepen the health inequality that already exists between rich and poor.
But the deeper fear is not just about access to therapy. It is about a two-tiered humanity: one layer whose genomes are enhanced by the latest technology, and another whose genomes remain unmodified. This is not science fiction. The National Academies of Sciences, Engineering, and Medicine in the United States have already taken a permissive-but-cautious stance. Bioethicist R. Alta Charo, quoted in the Guardian editorial, framed the question precisely: “Should it be employed at all, and if so, under what circumstances?”
The uncomfortable answer, from a global equity perspective, is that the “circumstances” will be determined by purchasing power unless we build regulatory guardrails now, while the technology is still maturing.
What Science Owes Humanity
Dieter Egli of Columbia University, lead author of one of the new base-editing studies, told the Guardian that “while the technology is not yet ready for clinical application, the advancements made will guide responsible research toward its eventual safe and effective use.”
The word “responsible” is doing a lot of work in that sentence. Responsible to whom? To patients with devastating genetic diseases, certainly, and the promise of gene editing for conditions like Huntington’s disease, Tay-Sachs, and cystic fibrosis is real. But also to a broader public that has not consented to a future in which genetic enhancement is a commodity available to the highest bidder.
Seventy nations, including the UK, currently have laws against heritable human genome editing. But laws can change, especially as public opinion shifts. The Ipsos data shows that support for therapeutic gene editing is strong and growing. The danger is that the therapeutic argument becomes a stalking horse for enhancement, that the technology crosses the line from medicine to customization not through a single visible decision, but through a thousand small commercial ones, each one justified as “just treating disease.”
Science should be used to help people in need. It should not become a luxury service for the wealthy to design their children. The time to build the regulatory architecture that ensures that outcome is now, before the technology races ahead of the ethics, and the market decides for us.
Based on: “The Guardian view on gene-edited humans: darker uses must be acknowledged alongside medical ones,” The Guardian editorial, July 5, 2026. Data and quotes from the editorial, the cited base-editing studies, the Nuffield Council on Bioethics, and the 2026 Progress Educational Trust/Ipsos poll.